CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the first grant for the Kay & McCaffrey patent. The patent is an early, “fundamental” patent in the RNAi therapeutics field based on the groundbreaking research by Drs. Anton McCaffrey and Mark Kay (McCaffrey et al. (2002) Nature 418, 38-39) who were amongst the first to demonstrate the ability to harness RNA interference in a living mammal. The Kay & McCaffrey patent is licensed exclusively to Alnylam through an agreement with Stanford University.
